Watch the "What This Means" video here
Outlook CEO, Russ Trenary underscores that LYTENAVA (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD
FRENCHTOWN, NJ / ACCESSWIRE / June 6, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Outlook Therapeutics, Inc. (Nasdaq:OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases.
As part of this "What This Means" segment, Russell Trenary, President and Chief Executive Officer of Outlook Therapeutics, discusses the Company's recently received European Commission Marketing Authorization for LYTENAVA (bevacizumab gamma) for the treatment of wet AMD.
The Virtual Investor "What This Means" segment featuring Outlook Therapeutics is now available here. Additional videos from the "What This Means" series are available on demand at .
About JTC Team
JTC is a fully integrated investor relations firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit or connect with the company on Twitter and LinkedIn.
Contact:
Jenene Thomas
JTC Team, LLC
T: +1 (833) 475-8247
jtc@jtcir.com
SOURCE: JTC Team, LLC